中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
22期
2208-2210
,共3页
贝伐珠单抗%辅助化疗%晚期转移性结直肠癌%临床疗效%安全性
貝伐珠單抗%輔助化療%晚期轉移性結直腸癌%臨床療效%安全性
패벌주단항%보조화료%만기전이성결직장암%림상료효%안전성
avastin%chemotherapy%metastasis colorectal cancer%clinical efficacy%safety
目的 评价贝伐珠单抗联合FOLFOX治疗晚期转移性结直肠癌的临床疗效及安全性. 方法 将64例晚期转移性结直肠癌患者分为对照组33例和试验组31例. 对照组予以FOLFOX化疗方案,奥沙利铂85 mg·m-2 +亚叶酸钙200 mg·m-2 +氟尿嘧啶400 mg·m-2 ,2周1次,2次为1个疗程;试验组在对照组基础上,加用贝伐珠单抗10 mg·kg-1 ,于化疗结束后的第2天开始静脉滴注,至少用4次,2周1次. 化疗2个疗程后,比较2组患者的临床疗效及不良反应发生率. 结果 试验组的客观有效率 41.94%显著高于对照组 18.18%( P<0.05 ).试验组的中位生存时间为12.6个月显著高于对照组9.1个月( P<0.05). 2组患者Ⅲ~Ⅳ级恶心呕吐、粒细胞下降及血小板下降等不良反应发生率比较差异无统计学意义( P>0.05). 结论 贝伐珠单抗联合FOLFOX化疗可有效地提高晚期结直肠癌患者的临床疗效,且不增加不良反应发生风险.
目的 評價貝伐珠單抗聯閤FOLFOX治療晚期轉移性結直腸癌的臨床療效及安全性. 方法 將64例晚期轉移性結直腸癌患者分為對照組33例和試驗組31例. 對照組予以FOLFOX化療方案,奧沙利鉑85 mg·m-2 +亞葉痠鈣200 mg·m-2 +氟尿嘧啶400 mg·m-2 ,2週1次,2次為1箇療程;試驗組在對照組基礎上,加用貝伐珠單抗10 mg·kg-1 ,于化療結束後的第2天開始靜脈滴註,至少用4次,2週1次. 化療2箇療程後,比較2組患者的臨床療效及不良反應髮生率. 結果 試驗組的客觀有效率 41.94%顯著高于對照組 18.18%( P<0.05 ).試驗組的中位生存時間為12.6箇月顯著高于對照組9.1箇月( P<0.05). 2組患者Ⅲ~Ⅳ級噁心嘔吐、粒細胞下降及血小闆下降等不良反應髮生率比較差異無統計學意義( P>0.05). 結論 貝伐珠單抗聯閤FOLFOX化療可有效地提高晚期結直腸癌患者的臨床療效,且不增加不良反應髮生風險.
목적 평개패벌주단항연합FOLFOX치료만기전이성결직장암적림상료효급안전성. 방법 장64례만기전이성결직장암환자분위대조조33례화시험조31례. 대조조여이FOLFOX화료방안,오사리박85 mg·m-2 +아협산개200 mg·m-2 +불뇨밀정400 mg·m-2 ,2주1차,2차위1개료정;시험조재대조조기출상,가용패벌주단항10 mg·kg-1 ,우화료결속후적제2천개시정맥적주,지소용4차,2주1차. 화료2개료정후,비교2조환자적림상료효급불량반응발생솔. 결과 시험조적객관유효솔 41.94%현저고우대조조 18.18%( P<0.05 ).시험조적중위생존시간위12.6개월현저고우대조조9.1개월( P<0.05). 2조환자Ⅲ~Ⅳ급악심구토、립세포하강급혈소판하강등불량반응발생솔비교차이무통계학의의( P>0.05). 결론 패벌주단항연합FOLFOX화료가유효지제고만기결직장암환자적림상료효,차불증가불량반응발생풍험.
Objective To evaluate the clinical efficacy and safety of avastin combined with FOLFOX in the treatment of advanced metastatic colorectal cancer.Methods Sixty-four patients with advanced meta-static colorectal cancer patients were divided into treatment group (31 cases) and control group (33 cases).Control group was treated with FOLFOX chemotherapy regimen, oxaliplatin 85 mg·m-2 +leucovorin 200 mg·m-2 +fluorouracil 400 mg·m-2 , once two week, 2 times for a course of treatment.Treatment group was based on the control group, and addition of bevacizumab 10 mg·kg -1 , in the second day after the start of intravenous chemotherapy, at least four times, two times a week to repeat.After two cycles of chemotherapy, the objective response rate and chemotherapy related adverse drug reactions were compared between the two groups.Results The objective response rates were 41.94%and 18.18% in treatment and control group with significant difference (P<0.05).The median survival of the treatment group were 12.6 months was much longer than that 9.1 months in control group ( P <0.05).But the grade Ⅲ-Ⅳchemotherapy related toxicity was not sta-tistical different between the two groups( P>0.05).Conclusion FOL-FOX combined with avastin can significantly improve the clinical efficacy in patients with metastasis colorectal cancer without increasing the risk of developing gradeⅢ-Ⅳadverse drug reactions.
